7. A compound according to claim **6** which is anhydrous.

8. A compound according to claim **6** which is a hydrate.

9. A compound according to claim **1** which is the meso-tartrate salt.

10. The L-tartrate salt of claim **2** that is a hydrate.

11. A compound according to claim **10** where the hydrate is a monohydrate.

12. A D,L-tartrate of claim **4** which is a hydrate.

13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims **1**, **2**, **6** or **9**.

14. A method of treatment for nicotine dependency, addiction and withdrawal comprising the administration of a compound according to any of claims **1**, **2**, **6** or **9** to a subject in need thereof.

15. A process for the preparation of a compound according to claim **1** comprising the steps of

(i) contacting 5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with between about 1 and about 2 equivalents of L-tartaric acid; and

(ii) collecting the crystals formed.

16. A process according to claim **15** wherein 1.1 equivalents of L-tartaric acid are employed and the tartaric acid is added to a solution containing the free base.

17. A process according to claim **15** wherein the contacting step is allowed to proceed above 45° C.

18. A process according to claim **15** wherein the contacting step is allowed to proceed for less than 2 hours.

19. A process according to claim **15** wherein the suitable solvent is selected from the group consisting of an (C_1–C_6) alkyl alcohol, an (C_1-C_6)alkyl ketone, an (C_1–C_6)alkyl ether, acetonitrile and an (C_1–C_6)alkyl ester.

20. A process according to claim **15** wherein the suitable solvent is ethanol or methanol.

21. A process for the preparation of a compound according to claim **1** comprising the steps of

(i) contacting 5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with between about 1 and about 2.3 equivalents of L-tartaric acid; and

(ii) collecting the crystals formed.

22. A process according to claim **21** wherein 1.1 equivalents of L-tartaric acid are employed and the free base in solution is added to a solution containing L-tartaric acid.

23. A process according to claim **21** wherein the contact step is allowed to proceed for at least 2 hours.

24. A process according to claim **21** wherein the contact step is allowed to proceed for at least 12 hours.

25. A process according to claim **21** wherein the suitable solvent is selected from the group consisting of an (C_1–C_6) alkyl alcohol, an (C_1–C_6)alkyl ketone, an (C_1–C_6)alkyl ether, acetonitrile and an (C_1–C_6)alkyl ester.

26. A process according to claim **21** wherein the suitable solvent is methanol or ethanol.

27. A process according to claim **21** wherein the suitable solvent is methanol.

28. A process for the preparation of a compound according to claim **16** comprising the steps of

(i) contacting an anhydrous L-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]-hexadeca-2(11),3,5,7,9-pentaene with water; and

(ii) collecting the crystals formed.

29. A process according to claim **28** wherein the contacting of step (i) comprises exposing the anhydrous L-tartrate salt to greater than 70% humidity.

30. A process according to claim **28** wherein the contacting of step (i) comprises slurrying the anhydrous L-tartrate salt with water.

31. A process according to claim **28** wherein step (i) comprises the addition of an organic solvent.

32. A process according to claim **28** wherein step (i) comprises the addition of methanol, ethanol or acetonitrile.

33. A process for the preparation of a compound according to claim **25** comprising the steps of

(i) contacting 5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with about 1 to about 2.3 equivalents of D,L-tartaric acid; and

(ii) collecting the crystals formed.

34. A process according to claim **33** wherein about 2.2 equivalents of D,L-tartaric acid is employed and the free base in solution is added to a solution containing D,L-tartaric acid.

35. A process according to claim **33** wherein the contact step is allowed to proceed for at least 24 hours.

36. A process according to claim **33** wherein the suitable solvent is anhydrous ethanol.

37. A process for the preparation of a compound according to claim **12** comprising the steps of

(i) contacting 5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]-hexadeca-2(11),3,5,7,9-pentaene in a suitable solvent with about 1 to about 2.3 equivalents of D,L-tartaric acid; and

(ii) collecting the crystals formed.

38. A process according to claim **37** wherein about 2.2 equivalents of D,L-tartaric acid is employed and the free base in solution is added to a solution containing D,L-tartaric acid.

39. A process according to claim **37** wherein the contact step is allowed to proceed for at least 24 hours.

40. A process according to claim **37** wherein the suitable solvent is 20% aqueous ethanol.

* * * * *